PRLD
Prelude Therapeutics IncorporatedNASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
3.17
P/S
15.88
EV/EBITDA
-1.72
DCF Value
$4.49
FCF Yield
-29.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
93.1%
Operating Margin
-861.3%
Net Margin
-819.6%
ROE
-130.0%
ROA
-70.4%
ROIC
-114.8%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $5.6M | $-16.5M | $-0.26 |
| FY 2025 | $12.1M | $-99.5M | $-1.29 |
| Q3 2025 | $6.5M | $-19.7M | $-0.26 |
| Q2 2025 | $0.00 | $-31.2M | $-0.41 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
0.71
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; PRT3645, a brain penetrant molecule that potently and selectively targets CDK4/6; and PRT-K4 that is in preclinical stage for solid tumors. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.